Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.68 |
| ▸ | EGLN2 | Q96KS0 | 13/20 | 0.68 |
| ▸ | EGLN3 | Q9H6Z9 | 13/20 | 0.68 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17629559 | 0.93 | EGLN1 (0.68) | EGLN1EGLN2EGLN3CYSLTR2KDM4E | |
| SCHEMBL17633154 | 0.92 | EGLN1 (0.66) | EGLN1EGLN2EGLN3CYSLTR2KDM4E | |
| SCHEMBL17629553 | 0.83 | EGLN1 (0.51) | EGLN1EGLN2EGLN3CYSLTR2KDM4E | |
| SCHEMBL20258261 | 0.83 | EGLN1 (0.73) | EGLN1EGLN2EGLN3CYSLTR2KDM4E | |
| SCHEMBL17629696 | 0.81 | EGLN1 (0.80) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL17629612 | 0.81 | EGLN1 (1.00) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL17629595 | 0.80 | EGLN1 (0.54) | EGLN1EGLN2EGLN3CYSLTR2KDM4E | |
| SCHEMBL17629630 | 0.79 | EGLN1 (0.72) | EGLN1EGLN2EGLN3CYSLTR2ALDH1A1 | |
| SCHEMBL17629549 | 0.79 | HDAC1 (0.47) | EGLN1EGLN2EGLN3CYSLTR2KDM4E | |
| SCHEMBL3777074 | 0.79 | EGLN2 (0.52) | EGLN1EGLN2EGLN3CYSLTR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197455-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3197455-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016049097-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | HIF1AN, HIF1A, EGLN2 | EGLN1 6/4885EGLN2 3/4885EGLN3 4/4885 |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 6/4885EGLN2 3/4885EGLN3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.